SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- PLEASE READ THIS NOTICE CAREFULLY AND COMPLETELY. YOUR RIGHTS MAY BE AFFECTED.
New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Avis Budget Group, Inc. ("Avis Budget Group, Inc.") (NASDAQ:
CAR shares plunge 21.8% after Q4 loss of $6.53 per share and revenue miss as Americas sales fall. The 2026 EBITDA guidance ranges from $800M to $1B.

New Strong Sell Stocks for February 20th

08:06am, Friday, 20'th Feb 2026
ARR, ARI and DKNG have been added to the Zacks Rank #5 (Strong Sell) List on February 20th, 2026.
Avis Budget Group, Inc.'s Q4 2025 results were a broad miss: $2.66B revenue vs. $2.75B Street, FY25 revenue $11.65B, missing consensus for the third straight year. The big shock was profitability with

Geopolitical Jitters Weigh on Wall Street

12:05pm, Thursday, 19'th Feb 2026
Stocks are lower, holding on to earlier losses, as geopolitical tensions between the U.S. and Iran resurface
Avis Budget Group, Inc. (CAR) Q4 2025 Earnings Call Transcript

Why Avis Budget Group Stock Just Crashed

11:10am, Thursday, 19'th Feb 2026
Avis Budget Group took a massive write-down on its EVs last quarter, tumbling the shares for a loss. Avis lost even more money in 2024 than in 2025, and might actually earn a profit in 2026.
Evaluate the expected performance of Avis Budget (CAR) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr
Avis Budget (CAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and exter
CAR Group Limited (CSXXY) Q2 2026 Earnings Call Transcript
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher Trial expansion reflects growing confide
BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeutic
IRVINE, Calif., Feb. 3, 2026 /PRNewswire/ -- Five Kia models were named winners of the 2026 Car and Driver Editors' Choice awards, recognizing vehicles that deliver top-notch performance, value, and d
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE